SCHEMBL202268

SCHEMBL202268

CSc1nc2cnc3cccnc3c2n1CCNC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
MTNR1A P48039 1/20 0.39
MTNR1B P49286 1/20 0.39
BCHE P06276 1/20 0.38
STING1 Q86WV6 3/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
DRD2 P14416 1/20 0.37
LATS1 O95835 1/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202649 0.85 KDM4E (0.41) KDM4EL3MBTL1TDP1BCHESTING1
SCHEMBL4156877 0.84 KDM4E (0.44) KDM4EL3MBTL1TDP1BCHESTING1
SCHEMBL12888449 0.84 KDM4E (0.44) KDM4EL3MBTL1TDP1BCHESTING1
SCHEMBL4147523 0.83 GAA (0.43) KDM4EL3MBTL1TDP1STING1CYP3A4
SCHEMBL3353897 0.83 TLR7 (0.47) KDM4EL3MBTL1TDP1STING1CYP3A4
SCHEMBL1231989 0.81 KDM4E (0.45) KDM4EL3MBTL1TDP1BCHESTING1
SCHEMBL5124567 0.80 STING1 (0.46) KDM4EL3MBTL1TDP1STING1CYP3A4
SCHEMBL5129239 0.80 STING1 (0.46) KDM4EL3MBTL1TDP1STING1CYP3A4
SCHEMBL3355952 0.78 TLR7 (0.48) KDM4EL3MBTL1TDP1STING1CYP3A4
SCHEMBL4309229 0.78 STING1 (0.46) KDM4EL3MBTL1TDP1STING1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
WO-2007106852-A2 SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 KDM4E 2419/4885L3MBTL1 3737/4885TDP1 4146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.